meRfi®-GM
Non-Alcoholic Steatohepatitis (NASH / MASH)
Welcome to meRfi-GM!
meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Navigation
Contents
Non-Alcoholic Steatohepatitis (NASH) is a severe form of non-alcoholic fatty liver disease (NAFLD) characterized by hepatic steatosis, liver inflammation, fibrosis and damage due to fat accumulation.
[AMPK Pathway / AMP-activated protein kinase (AMPK)](brain://p4UbdcTp_ES4Dnnqk2hgeQ/AmpkPathwayAMPactivatedProteinKinaseAmpk…
References (Sources)
- Cenicriviroc for the treatment of non-alcoholic steatohepatitis and liver fibrosis
- Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH.
- Gut symbionts alleviate MASH through a secondary bile acid biosynthetic pathway
- Imaging Biomarkers of NAFLD, NASH, and Fibrosis
- Inflammatory Mechanisms Underlying Nonalcoholic Steatohepatitis and the Transition to Hepatocellular CarcinomaReview
- NAFLD and Cardiovascular Diseases: A Clinical Review
- Nonalcoholic steatohepatitis (NASH) cirrhosis: a snapshot of therapeutic agents in clinical development and the optimal design for clinical trials